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Glomerular hypertension, abnormal glomerular growth, and uating vicious cycle, whereby loss of nephrons due to
progression of renal diseases. The development and progres- sclerosis further increased flow and pressures in re-
sion of sclerosis is determined by complex interactions of many maining glomeruli, thus augmenting and perpetuatingmechanisms, including direct hemodynamic actions, modula-
injury. We performed serial micropuncture studies intion of glomerular cell injury, and growth factor actions. The
the same model to investigate whether hemodynamicinterplay of these factors determines the balance of cell growth
and proliferation versus cell death by necrosis or apoptosis, derangement predicted the ultimate severity of sclerosis
and the balance of matrix accumulation versus degradation. in those same punctured glomeruli. At sacrifice, these
Sclerosis may even be reversed when therapies inhibit these same micropunctured glomeruli were identified, pro-mechanisms and augment matrix degradation processes, both
cessed and histologically assessed for sclerosis. The scle-by directly increasing proteolytic activity and by down-regulat-
rosis indices for the individual glomeruli were then corre-ing inhibitors of matrix degradation. We will focus in this review
on the roles of glomerular hemodynamics and growth in the lated with either maximum single nephron glomerular
progression of renal diseases. filtration rate (GFR), glomerular pressure, or average
values for these parameters as assessed by repeated mi-
cropuncture in these same glomeruli over the precedingGLOMERULAR HYPERTENSION
weeks [5]. There was no correlation between the degreeAND SCLEROSIS
of total sclerosis and these hemodynamic variables inHypertension accelerates progression of chronic renal
individual glomeruli, suggesting additional nonhemody-disease in humans, whether it results from, or causes,
namic factors contribute to sclerosis.the renal disease. Glomerular pressure can be modulated
Clinical data have shown superior efficacy on progres-differentially from systemic blood pressure. The poten-
sion of ACEI over nonspecific antihypertensive therapy,tial impact of these local glomerular hemodynamic
not attributable to blood pressure effects [6]. Cell culturechanges on sclerosis has been extensively studied in the
studies indeed show that angiotensin II (Ang II) canMunich-Wistar rat because it has superficial glomeruli,
directly induce mesangial cell hypertrophy and/or prolif-which can be directly punctured to measure glomerular
eration, depending on culture conditions, and increaseblood pressures and flows. The remnant kidney model,
extracellular matrix (ECM) production [7]. We thereforewhere 5/6 of the total renal parenchyma is removed,
examined the possibilities that ACEI in doses higherresults in progressive hypertension, proteinuria and ma-
than those required to lower increased blood pressuretrix expansion, culminating in focal segmental glomeru-
might have further beneficial effects [8]. The severity oflosclerosis, mimicking key aspects of progressive injury
glomerulosclerosis was assessed by renal biopsy at 8in humans [1–3]. Anderson et al [4] showed superior
weeks after 5/6 nephrectomy. Animals were then dividedprotection against progressive sclerosis in this model with
into groups that received no treatment, usual antihyper-angiotensin I-converting enzyme inhibitor (ACEI) com-
tensive dose of ACEI, or a four-fold higher dose ofpared to nonspecific antihypertensive treatment. Al-
ACEI. Both systemic and glomerular pressures werethough systemic pressures were normalized with both
normalized by both ACEI doses, with no further hemo-interventions, glomerular pressures were decreased only
dynamic effects at the higher dose. Progression of sclero-by ACEI, and remained high with nonspecific therapy.
sis was seen in all untreated animals from biopsy toThis led to the postulate of increased capillary pressure
autopsy. Progression of sclerosis was significantly amel-as a key mediator of progressive sclerosis in a self-perpet-
iorated in animals receiving the normal ACEI dose. Re-
markably, sclerosis was even further ameliorated and
Key words: glomerular cell injury, proliferation, chronic renal disease. even regressed in response to the four-fold higher ACEI
dose, with less sclerosis at autopsy than at biopsy 4 weeksÓ 2000 by the International Society of Nephrology
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Table 1. Conditions with glomerular hypertrophy and sclerosispreviously in three of the five rats. An angiotensin type
1 receptor antagonist (AIIRA) was similarly effective, Animal Models Human Diseases
achieving regression in half of the rats. This regression Remnant kidney FSGS
Puromycin nephropathy Unilateral renal agenesiswas associated with marked inhibition of plasminogen
Bcl22/2 mice Extensive loss of renal massactivator inhibitor-1 (PAI-1) protein expression (see be-
Os1/1/Rop mice Oligomeganephronia
low) (abstract; Nakamura et al, J Am Soc Nephrol Diabetic modelsa Diabetes
High protein diet Reflux nephropathy10:665A, 1999). Similar reversal of sclerosis by ACEI or
Angiotensin infusion Sickle cell diseaseAIIRA was observed in the nonhypertensive puromycin
Growth hormone or IGF-1 Eclampsia
aminonucleoside model of glomerulosclerosis by us and administration Cyanotic heart disease
Obesity/sleep apneaothers [9, 10].
The impact of hemodynamic vs. other factors on pro- aAssociated with mesangial expansion, not sclerosis, in rodent models
Abbreviations: Os, oligosyndactyly mouse; FSGS, focal segmental glomerulo-gressive injury at the single glomerular level was investi-
sclerosis; IGF-1, insulin-like growth factor-1.
gated in the ureteral diversion model [11]. The ureter
of one kidney was diverted into the peritoneum with
partial ablation of the contralateral kidney, resulting in
marked glomerular hyperperfusion and hyperfiltration well as growth. The tight linkage of glomerular enlarge-
and increased glomerular pressure. These changes, how- ment with glomerulosclerosis is thus postulated to be
ever, were accompanied by only minimal glomeruloscle- due to the actions of multiple factors on the glomerular
rosis, and only minimal glomerular enlargement oc- cells with a response of matrix, hypertrophy and prolifer-
curred. In contrast, in the 5/6 nephrectomy model, ation often occurring in concert (Fig. 1). Recent in vitro
marked glomerular enlargement occurred and was data based on sophisticated microchip gene array analy-
closely associated with glomerulosclerosis. Glomerular sis indeed show that the early fibroblast response to
enlargement and sclerosis were also closely correlated at growth factors includes not only genes implicated in cell
an individual glomerular level in a biphasic distribution, division, but also genes involved in wound healing and
with positive correlation of glomerular enlargement and angiogenesis [13]. These findings indicate tight linkage
sclerosis at early phases of sclerosis (i.e., up to 50% between growth, differentiation and wound healing/re-
of the tuft involved) and a negative correlation as the modeling responses.
glomeruli became smaller as progressive sclerosis devel-
oped until obsolescence occurred [12]. The ACEI effect
GLOMERULAR HYPERTROPHY INin ameliorating sclerosis in the remnant kidney model
EXPERIMENTAL MODELSwas associated with inhibition of glomerular growth,
Stimuli that have been shown in experimental condi-while maintaining the correlation of sclerosis and glo-
tions to promote growth and glomerulosclerosis includemerular size. Of note, ACEI was not equally effective
loss of renal mass, high protein or high salt diet, variousat all stages of fibrosis; progressive deterioration contin-
hormones such as growth hormone, insulin-like growthued in glomeruli with more advanced sclerosis despite
factor (IGF), androgens, and glucocorticoids; and vaso-ACEI, whereas progression was inhibited in glomeruli
active molecules such as angiotensin or endothelin [14].at earlier stages of sclerosis. These findings suggest that
Hypertrophic stimuli accelerate sclerosis, while interven-different mechanisms of sclerosis were active among the
tions that dampen glomerular hypertrophy often alsoheterogeneously affected glomeruli, with different po-
ameliorate glomerulosclerosis. The latter include lowtentials for response to treatment and remodeling. These
protein or low salt or low phosphate diet, ablation ofdata indicate that abnormal glomerular growth is associ-
androgen effects by castration, antagonism of growthated with, and may be a marker of mechanisms leading
hormone with octreotide, a somatostatin analog, geneticto sclerosis. These experiments also indicate that hyper-
defects in growth hormone or inhibition of angiotensinfiltration alone is insufficient to induce pathogenic glo-
or endothelin.merular hypertrophy and subsequent sclerosis.
The hypertrophic response and subsequent develop-
ment of sclerosis are dependent on the genetic back-
ABNORMAL GLOMERULAR GROWTH ground, suggesting that complex genetic traits modulate
AND SCLEROSIS the response of glomerular cells to pathogenic stimuli.
Mice with reduced nephron number due to a radiation-Glomerular hypertrophy and sclerosis are linked in
numerous diseases in humans and in experimental ani- induced mutation that results in ,50% nephron reduc-
tion in association with oligosyndactyly (Os1/1) devel-mal models (Table 1). In vivo and in vitro experimental
evidence point to the capability of many cytokines to oped severe glomerular enlargement and sclerosis when
this abnormality occurred on the sclerosis-prone ROPpromote growth of glomerular cells and also to enhance
extracellular matrix release, thus promoting sclerosis as genetic background, but not in C57 mice [15]. Glomeru-
Fogo: Glomerular hypertension and abnormal growth S-17
Fig. 1. Glomerular hypertrophy is postulated
to be associated with glomerulosclerosis based
on the linked responses of glomerular cells to
growth stimuli. Hypertrophy and proliferation
thus typically occur in concert with increased
ECM release. ECM accumulation is the cor-
nerstone of sclerosis.
lar hypertrophy was proportional to reduction of neph- course and re-biopsy consistent with this diagnosis were
compared to patients with similar initial biopsies butron mass in the former strain. In contrast, a threshold
for glomerular size was observed in the C57 mice. The who subsequently developed overt focal segmental glo-
merulosclerosis. These biopsies were then compared tointerplay of genetic background and response to injury
is also well recognized in humans, where only ,40% of age-matched controls [17]. Whereas patients with mini-
mal change disease showed normal glomerular size, ini-patients with type 1 diabetes mellitus develop diabetic
nephropathy (see below). tial biopsies in patients with progression to focal segmen-
tal glomerulosclerosis revealed significant glomerularThe age of injury also modifies the growth response
to renal ablation. In young animals where maturational enlargement. Similarly, in adults with focal segmental
glomerulosclerosis, glomeruli were larger than in thosegrowth is occurring, injury after renal ablation was more
severe than in adults [16]. Hemodynamic factors were with minimal change disease [18]. The association of
increased glomerular size and subsequent evolution ofnot different among the two age groups. Although glo-
merular enlargement occurred to greater degree in the glomerular sclerosis was also seen in the setting of recur-
rent FSGS in the transplant. Thus, in cases of nephroticyoung compared to the adult rat after renal ablation,
glomerular enlargement occurred proportionally in both syndrome without evident segmental glomerular sclero-
sis, patients with normal glomerular size appear to have asuperficial and deep nephron populations, with more
severe glomerulosclerosis in deep nephrons in young good prognosis. In contrast, those patients with markedly
enlarged glomerular size have a high risk of subsequentanimals. This increased sclerosis was postulated to be
related to factors unique in the young growing kidney, progression to overt FSGS. A recent genetic analysis of
children with nephrotic syndrome found FSGS patientswhich is characterized by centripetal growth and differ-
entiation. to have a higher prevalence of the ACE deletion (D)
polymorphism, compared to the insertion (I) polymor-
phism, when compared to minimal change disease pa-
GLOMERULAR HYPERTROPHY AND tients [19]. This D allele has been associated with higher
HUMAN DISEASE activity of the renin angiotensin system (RAS), which
Glomerular hypertrophy is linked with development may influence both renal growth and scarring responses.
of sclerosis in human disease [14]. Stimuli to abnormal
growth noted in humans include hypoxia, as seen in
LOSS OF RENAL MASS IN HUMANScyanotic heart disease, sickle cell disease and obesity-
associated sleep apnea; and limited renal mass, as in Response to decreased renal mass in humans varies
according to age at loss, underlying condition and extenttransplantation, extensive removal of renal mass and
unilateral renal agenesis. All of these conditions have of tissue loss. Several follow-up studies conducted on
renal transplant donors as well as individuals nephrecto-also been associated with lesions of focal segmental glo-
merulosclerosis (FSGS). In human diabetes and FSGS, mized secondary to trauma and unilateral diseases sug-
gest a relatively benign course after unilateral nephrec-increased glomerular size precedes development of the
sclerotic lesions. Patients with initial biopsies consistent tomy [14, 20]. In contrast, patients with nephrectomy for
unilateral disease show a surprisingly high incidence ofwith minimal change disease and with subsequent clinical
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glomerular sclerosis developing in these remnant kid- wards normal after injury. Renal growth occurs by both
hyperplasia (increase in cell number) and hypertrophyneys. The reason for this apparent difference between
response to these two forms of nephrectomy may be (increase in cell size). Increases in renal mass primarily
reflect tubular growth. However, glomerular growth alsomultifactorial, including recurrence of the primary dis-
ease in the therapeutically nephrectomized patients and occurs in response to some injuries or reduced nephron
mass. The glomerular growth occurs primarily by length-selection of individuals without risk factors for renal
disease as kidney donors. In contrast, more extensive loss ening of the capillaries without significant increase in
diameter after loss of renal parenchyma or in childrenof renal mass in patients with bilateral tumors resulted in
an increased incidence of FSGS in the remnant kidney with reflux nephropathy [27, 28]. In contrast, growth is
accomplished by new capillary branching in experimen-[21]. Age at loss of renal mass influences the renal re-
sponse in humans. In patients undergoing unilateral ne- tal diabetes and in toxic nephropathy due to lithium [29,
30]. With more extreme hemodynamic abnormalities,phrectomy for Wilms’ tumor, renal growth was most
marked in those who had surgery at a younger age, dilatation of capillaries may occur and contribute to in-
creased glomerular size [31].and this increased kidney growth was associated with
microalbuminuria that developed in 11 of 34 patients So-called glomerular hypertrophy, that is an increase
in glomerular size, represents both cellular hypertrophy[22]. In 157 patients with unilateral renal agenesis, there
was significantly increased risk for proteinuria (in 19%), and hyperplasia. Glomerular hypertrophy can be de-
tected biochemically and morphologically by electronhypertension (47%) and renal insufficiency (13%), with
death due to renal disease in 6 patients [23]. The worse microscopy as early as 2 days after 5/6 nephrectomy.
Increased glomerular volume at 2 days was attributableprognosis in these patients compared to the benign out-
comes following unilateral nephrectomy for trauma or to increased glomerular visceral epithelial cell expansion,
likely hypertrophy in view of this cell’s limited mitogenicin donors suggests that the number of remnant nephrons
in the congenital solitary kidney may, in fact, be de- capacity (see below) [32]. Later increases in glomerular
volume were contributed to by mesangial cell increase,creased (i.e., hypogenesis), thereby representing a more
likely both hypertrophy and hyperplasia. Hyperplasiasevere form of reduction in nephron population than
predominated after 5/6 nephrectomy, whereas hypertro-surgical unilateral nephrectomy. The possibility that the
phy was the major growth response after uninephrec-remnant glomeruli of congenital solitary kidney are un-
tomy. The resulting glomerular growth was more markedder greater hypertrophic stress is indeed supported by
after 5/6 nephrectomy, and was associated with laterquantitative morphometric studies. The volume of each
sclerosis.glomerulus in solitary kidneys was found to be 5–6 times
The precise trigger(s) for initiation of growth responsenormal, a value closer to that found in oligomega-
remain undetermined. Early work proposed that renalnephronia than that seen in postnephrectomized adults
growth after uninephrectomy was merely in response to[24]. Oligomeganephronia is another congenital condi-
increased work load. In the early 1970s the concept oftion in humans characterized by few but markedly en-
“renotropic” factor(s) was formulated as the alternativelarged nephrons, and perhaps increased risk of FSGS.
explanation based on observations of renal growth inLower nephron number may be associated with in-
normal animals connected by parabiosis with an anephriccreased risk of renal disease in the population with two
partner, resurrecting observations made by Sacerdottiapparent normal kidneys as well. Glomerular size in
over a hundred years ago [14, 33]. Most recently, a possi-normal African Americans is larger than in Caucasians,
ble quantitative trait locus (QTL) linked to genetic mod-and could possibly reflect smaller nephron number [25].
ulation of the compensatory growth response has beenDecreased nephron number has been postulated to occur
identified in the mouse on chromosome 11. This markersecondary to low birth weight [26]. The latter is associ-
maps near the genes for ACE, growth hormone andated with increased risk for progressive renal disease in
neural growth factor receptor (NGFR), all of which haveadulthood. Other possible mechanisms that could under-
known influences on growth responses in the kidney [34].lie these differences in normal glomerular growth and
Hypertrophy of remnant glomeruli was also postulatedalso relate to the well-documented increased incidence
to be the consequence of the abnormal hemodynamicsof end stage renal disease in the African American popu-
developing within these glomeruli or merely representlation include polymorphisms of genes involved both in
engorgement. However, the increased growth in the rem-renal/glomerular development and in scarring mecha-
nant kidney model in the rat occurred before increasesnisms, such as the renin angiotensin system.
in single nephron GFR [14].
Altered gene expressions in pathophysiologic settings
FACTORS MEDIATING GROWTH implicate many factors in glomerular growth and en-
Adaptations to increase renal mass and function pre- hanced ECM release, including the following: platelet
derived growth factor (PDGF), transforming growthsumably occur in attempts to restore renal function to-
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factor-b (TGF-b), TGF-a, IGF-1, growth hormone, epi- well as proliferation and migration occur in several ani-
mal models of glomerular injury. The balance betweendermal growth factor, interleukins 1 and 6, tumor necro-
sis factor-a (TNF-a), Ang II, hepatocyte growth factor endothelial cell growth and death appear to be crucial
for determining whether healing or scarring will resultand its receptor c-myc, and endothelin. Several growth
factors are now considered to play key causal roles in after injury [37]. Normally, endothelial cells inhibit
smooth muscle cell migration and proliferation. Endo-glomerulosclerosis, including Ang II, PDGF and TGF-b,
based on results of infusion, transfection and inhibition thelial cells produce numerous factors that modulate
mesangial or vascular smooth muscle cell growth (e.g.,of these factors. Studies in human renal diseases have
begun to map some of these key growth factors, showing vascular endothelial growth factor, VEGF; nitric oxide;
endothelin and PDGF) [18]. Some endothelial-derivedup-regulation in some settings. Interpretation must take
factors act in synergy with heparin-like substances.into account that a given growth promoter may affect
VEGF is an endothelial cell-specific mitogen that withindifferent cells differently, inducing proliferation, hyper-
the kidney originates largely from epithelial cells, andtrophy or even inhibiting growth, depending on the host
may mediate physiologic and pathologic angiogenesis.cells’ milieu, genotype and phenotype.
Recent evidence implicates VEGF as a necessary sur-
vival factor for cells in vivo (abstract; Suga et al, J Am
METABOLIC FACTORS PROMOTING Soc Nephrol 10:561A, 1999). Endothelin, a powerful va-
RENAL GROWTH soconstrictor, is released from endothelial cells in re-
Abnormal renal growth precedes development of scle- sponse to a variety of stimuli and also after injury [38].
rosis in diabetic nephropathy. IGF-1 is one key growth Endothelin results in the adaptive responses of hyperpla-
factor altered in progressive renal diseases, including sia, hypertrophy and increased matrix in mesangial cells
diabetes. Several other growth factors including basic in culture [18, 38]. Plasminogen activator-inhibitor-1,
fibroblastic growth factor (bFGF), PDGF and epidermal PAI-1, which is produced by endothelial cells among
growth factor, may be altered in diabetes and affect other sources, has been linked to not only thrombosis,
glomerular growth and sclerosis. Patients with diabetic but also fibrosis through its effects to inhibit matrix deg-
nephropathy showed significantly larger mean glomeru- radation [39]. PAI-1 induction occurs in response to sev-
lar size and mesangial volume compared to both normal eral growth factors and cytokines that play key roles in
controls and diabetics without nephropathy [35]. In addi- renal growth and fibrotic responses, including TGF-b
tion, there was a strong correlation between severity of and angiotensin. These data indicate that PAI-1 may be
glomerular sclerosis and glomerular hypertrophy. The an additional target for antifibrotic therapies.
potential importance of the diabetic milieu in promoting The glomerular visceral epithelial cell is part of the
capillary wall barrier, and produces ECM. Glomerularthe glomerular hypertrophy and mesangial matrix expan-
visceral epithelial cells have limited capacity for hyper-sion of diabetic nephropathy was evident in a study of
plasia. The exciting recent discoveries of specific cyclin-diabetic patients with renal and pancreas transplants.
dependent kinase inhibitors expressed in mature, but notPatients with the combined transplants, who achieved a
immature glomerular visceral epithelial cells suggest ametabolic cure of their diabetes, had only minimal mesan-
possible mechanism for this limitation of this highly spe-gial expansion in their transplant kidneys. Long-term
cialized cell [40]. Manipulations of one of these inhibi-follow-up even showed reversal of sclerosis in some of
tors, p27Kip-1, in experimental mice models illustratedthese patients [36]. The pancreas transplant patients also
that abnormal glomerular visceral epithelial cell prolifer-had smaller mean glomerular volume and mesangial vol-
ation, whether too little or too much, resulted in aug-umes than control patients. In contrast, diabetic patients
mented glomerular injury [40]. Epithelial cells frequentlyreceiving only kidney transplant who thus remained dia-
are detached from the underlying basement membranebetic, showed more severe diabetic renal lesions.
in settings of glomerular hypertrophy and sclerosis, per-
haps due to their limited growth. These epithelial cell
CELL-SPECIFIC GROWTH RESPONSES defects are postulated to play an important role in adhe-
Glomerular growth may occur due to increase in any sions and hyalinosis, leading to progressive scarring [41].
of its cellular components. These alterations in response Glomerular visceral epithelial cells also interact with
to either the initial injury or to a decrease in remaining other glomerular cells and modulate cell growth and
renal mass after initial injury contribute to maintaining matrix synthesis/degradation by elaboration of growth
renal function in the short term. However, in the long factors and cytokines, such as heparan (inhibits mesan-
term these adaptive changes promote matrix accumula- gial cell growth) and VEGF. Injured glomerular visceral
tion and thereby renal malfunction. epithelial cells also change phenotype. The Wilms’ tumor
The glomerular endothelial cell has a long half-life, gene WT-1, normally expressed in glomerular visceral
epithelial cells, is decreased or lost in injured glomerularapproximately 100 days. Endothelial cell apoptosis as
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visceral epithelial cells in the severe collapsing form of creased growth factors, which may be induced in re-
sponse to various stimuli. The final result of these pro-FSGS, a dedifferentiation phenotype [42]. WT-1 has
been implicated in a wide spectrum of functions in the cesses is increased matrix accumulation, the root cause
of sclerosis. The particular growth factors and the roleskidney, including renal development, glomerular perm-
selectivity and sclerosis. they play may differ at the various stages of injury. The
contribution of angiotensin II is particularly relevantThe mesangial cell responds to many growth factors by
proliferation and increased ECM synthesis. After initial since it can be inhibited by currently clinically available
agents. The potential regression of glomerular sclerosisinjury, the activated mesangial cell changes phenotype,
expressing fibroblast-like myosin [43]. This wound heal- has now been shown in human diabetic nephropathy.
Animal studies point to PAI-1 as a key target in achievinging phenotype is associated with increased matrix gener-
this remodeling of matrix, however, the specific factorsation. a-actin expression is also increased after injury,
that could optimize regeneration of open capillary loopsalong with increased PDGF-B, recapitulating their de-
have not been identified. Further study is necessary tovelopmental patterns of expressions in mesangial cells.
determine the specific role each of these factors plays inAng II induces mesangial cell hypertrophy and increases
varying settings of renal growth to maximize beneficialmatrix production from mesangial cells in vitro. TGF-b
growth responses and inhibit those deleterious to kidneyincreases both collagen and proteoglycan production by
function and structure.mesangial cells, and depending on the cell cycle stage,
acts synergistically with other growth factors. bFGF may
Reprint requests to Agnes B. Fogo, M.D. MCN C3310, Department of
initiate mesangial cell injury response. Mesangial cells Pathology, Vanderbilt University Medical Center, Nashville, Tennessee,
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